First description of rpsJ and mepA mutations associated with tigecycline resistance in Staphylococcus aureus isolated from a cystic fibrosis patient during antibiotic therapy

HAIM, M.S.; DI GREGORIO, S.; GALANTERNIK, L.; LUBOVICH, S.; VÁZQUEZ, M.; BHARAT, A.; ZAHEER, R.; GOLDING, G.R.; GRAHAM, M.; VAN DOMSELAAR, G.; CARDONA, S.T.; MOLLERACH, M.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

ELSEVIER SCIENCE BV

Año: 2017 vol. 50 p. 739 - 741

0924-8579

Vancomycin remains the gold standard of treatment for methicillin-resistant Staphylococcus aureus (MRSA) serious infections; however, the emergence of strains with reduced vancomycin susceptibility warrants the need for alternative therapies. Tigecycline (TGC) is a broad-spectrum protein synthesis inhibiting antibiotic that is active against Gram-positive and Gram-negative organisms, including multidrug-resistant (MDR) bacteria. The FDA approved its use for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. Multiple studies have described a very low frequency (< 0.001%) or complete absence of TGC resistance in S. aureus. Here, we report the first case of TGC non-susceptible S. aureus clinical isolates associated with mutations in rpsJ and mepA genes